C0243095||Recognition
C0243095||Early Cardiac Involvement
C0027061||tissue
C0243095||recognition
C0027061||myocardial
C1304881||biopsy-proven
C0011900||extracardiac diagnosis
C0025266||men
C2712122||normotensive
C0025266||men
C3887460||cardiovascular
C0024485||magnetic resonance imaging
C0232164||cardiac function
C2936236||late gadolinium enhancement
C1522577||follow-up
C2603343||substudy
C0087111||anti-inflammatory treatment
C0936012||analyses
C0012634||disease
C0871608||Wilcoxon signed rank test
C1518681||effect of treatment
C1522564||myocardial
C0243095||longitudinal strain
C2700378||ejection fraction
C1522564||Myocardial
C0679228||diagnostic criteria
C0012634||disease
C0441610||significant reduction
C0087111||treatment
C0205160||not
C0205160||not
C0027061||myocardial tissue
C0814177||noninvasive recognition
C0243095||cardiac involvement
C0027059||myocardial inflammation
C2603343||studies
C1514983||stratification
C0150600||guidance
C1516615||clinical management